BEACONPHAR Beacon Pharmaceuticals Limited
Pharmaceuticals & Chemicals
Tk 92.8 as of 2026-11-12 14:03:31
Rank 65 of all scored
Data completeness 100%
Data completeness 100%
Score breakdown
Consistency 85
Profitability 66
Solvency 54
Valuation 60
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Consistency EPS grew in 3 of 4 years
- Consistency Paid a dividend every year (5/5)
- Valuation P/E 11.03 is low (general benchmark ≤ 12)
- Ownership Institutions (38.15%) hold more than the public (21.75%)
Notes
- Profitability Average ROE 12.17% (moderate)
- Solvency Debt/equity 1.22x (healthy but risky)
Risk flags
- Within 5.94% of its 52-week low: check WHY before treating it as cheap
Valuation
P/E
P/E audited
P/E current
P/B
NAV per share
EPS (last audited year)
Graham fair value
Margin of safety
52-week range
5.9% above the low, 21.3% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
ROE
ROE avg
ROE min
Profit CAGR
Profit YoY
Net profit
EPS up
Loss years (last ~5)
Dividends and safety
Div years
Dividend yield
Payout
Cash div
D/E
Loans/MCap
Size, liquidity and ownership
MCap
Free float
Daily turnover
Sponsor %
Inst. %
Public %
Foreign %
Shareholding
- Sponsor/director 39.9%
- Institution 38.2%
- Foreign 0.2%
- Public 21.8%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2021 | 3.74 | 23.18 | 86 | 15 | 0 |
| 2022 | 4.05 | 25.73 | 94 | 16 | 0 |
| 2023 | 2.21 | 25.72 | 51 | 16 | 0 |
| 2024 | 2.26 | 26.37 | 52 | 20 | 0 |
| 2025 | 4.1 | 28.86 | 95 | 21 | 0 |
Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 47%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.